Chances Clovis Oncology Inc. (NASDAQ:CLVS) could heat up?

913

Clovis Oncology Inc. (NASDAQ:CLVS), whose market capitalization now stands at $3.92B, reported EPS of $-8.23 in the last financial year. That indicates the stock has price-to-earnings ratio of – at the prevailing stock price. This fiscal year’s EPS is projected to grow 7.40% over the preceding year.

For the forward P/E metric, market analysts have a 12-month target price of $70.00 on the stock of Clovis Oncology, Inc..

Over the preceding five years, Clovis Oncology, Inc. has recorded EPS improvement of -29.60%. That against sales growth of -% over the same 5-year period. For the imminent five years, analysts expect the firm to post EPS growth of 31.90%.

Let’s look into the charts of the stock

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction. Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The company posted free cash flow of $(83.01M).

Clovis Oncology, Inc. also recorded return assets of -73.40%, return on of -380.90%.

Analysts are projecting the stock of Clovis Oncology, Inc. to be trading at $70.00 in the next 12-months, but what been its performance quality until now?

The stock jumped/declined 46.25% in the previous week, and for the preceding month it is up/down 60.86%. For the quarter and for the fiscal year so far, the shares have risen/decline 25.45% and 97.84%, respectively. From a year earlier, the stock has moved 552.90%.

What about the volatility of the equity? First, the stock’s beta is 1.67. Investors would do well to note that beta of less than 1 indicates that the underlying security is less volatile as against the market, but beta over one implies that a security is extremely volatile compared to market.

In terms of monthly or weekly volatility, Clovis Oncology, Inc. has a weekly volatility of 5.63% and monthly volatility of 5.13%.

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $250 million. All shares of the common stock to be sold in the offering will be offered by Clovis Oncology.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.